TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23968769
Drug: rWN/DEN4Δ30 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rWN/DEN4Δ30 vaccine at 10⁵ PFU (second dose)
Study: 22068922
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch (17.4 mg/24 h)
Study: 22068922
Drug: Rivastigmine capsule
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsule (12 mg/day)
Study: 15668708
Drug: GT after
Approvals — FDA: no, EMA: no, PMDA: no
Description: GT after chemotherapy
Study: 8750368
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intravenous lamivudine (administered over 1 hour)
Study: 8750368
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral lamivudine (1 mg/mL)
Study: 8750368
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet
Study: 8750368
Drug: All oral
Normalized name: Exall Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: All oral formulations (oral solution, capsule, tablet)
Study: 27935458
Drug: Group session
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group session of hypnosis with a hypnotic induction (n = 84)
Study: 27935458
Drug: No-induction group
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-induction group receiving identical suggestions without a hypnotic induction (n = 83)
Study: 23359433
Drug: Adjuvant lapatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO)
Study: 20012308
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg daily for 6 months
Study: 17531764
Drug: HPV-16/18 L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 L1 VLP AS04 vaccine administered at months 0, 1, and 6
Study: 17531764
Drug: HPV-16/18 L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 L1 VLP AS04 vaccine
Study: 15663340
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (ethinylestradiol/drospirenone)
Study: 15663340
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (ethinylestradiol/cyproterone)
Study: 15663340
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (ethinylestradiol/desogestrel)
Study: 15663340
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (ethinylestradiol/gestodene)
Study: 15663340
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (ethinylestradiol/chlormadinone)
Study: 15663340
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (ethinylestradiol/levonorgestrel)
Study: 15663340
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (ethinylestradiol/norethindrone)
Study: 15663340
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (ethinylestradiol/norgestimate)
Study: 11680569
Drug: Thymoglobulin (rabbit
Normalized name: Thymoglobulin (rabbit)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (rabbit anti‐thymocyte globulin), 1.5 mg/kg/day for 6‐14 days
Study: 9477711
Drug: Consolidated Standards
Normalized name: Stangard
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consolidated Standards for Preparation of Controlled Clinical Trials (CONSORT) checklist
Study: 7861706
Drug: Before angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before angiotensin infusion
Study: 7861706
Drug: During angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During angiotensin infusion
Study: 26178501
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control (stable blood glucose at 6.1‐8.3 mmol/L)
Study: 23201367
Drug: Strong placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strong placebo treatment
Study: 23201367
Drug: Weak placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weak placebo treatment
Study: 23201367
Drug: Placebo treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatments (both strong and weak)
Study: 21694454
Drug: Transdermal 17‐β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17‐β estradiol (unopposed and opposed with medroxyprogesterone) for 12 months
Study: 16148997
Drug: Multiple cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple cancer group (MCG)
Study: 11822980
Drug: Phytoestrogens and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogens and selective estrogen receptor modulators
Study: 9442338
Drug: (-)-3PPP, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-3PPP, 300 mg B.I.D. in early efficacy study
Study: 2643894
Drug: Droperidol, 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol, 0.075 mg/kg
Study: 2643894
Drug: Lidocaine, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine, 1.5 mg/kg
Study: 2643894
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lidocaine, 1.5 mg/kg and droperidol, 0.025 mg/kg
Study: 29949407
Drug: Acute intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute intravenous hypertonic saline infusion (HSI)
Study: 27060853
Drug: Sertraline/Olanzapine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline/Olanzapine combination treatment
Study: 23363721
Drug: Domestic hydrochloric
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic hydrochloric trimetazidine capsules
Study: 23363721
Drug: Imported hydrochloric
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported hydrochloric trimetazidine tablets
Study: 8002198
Drug: Survey questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survey questionnaire utilizing a 30-day recall period with the combination of cough, fast breathing or shortness of breath, and fever.
Study: 30033645
Drug: Ginger root
Normalized name: Ginger Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger root supplement (60 mg of active gingerols/day, four capsules)
Study: 25801058
Drug: Tong Xin
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tong Xin Luo + Simvastatin 20 mg (after 7 days of TCM)
Study: 25801058
Drug: Nao Xin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nao Xin Tong + Simvastatin 20 mg (after 7 days of TCM)
Study: 25801058
Drug: Guan Mai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guan Mai Ning + Simvastatin 20 mg (after 7 days of TCM)
Study: 25801058
Drug: Yin Xing
Normalized name: ALLOGENIC ADIPOSE DERIVED MESENCHYMAL STEM CELLS (MSCS) EXOSOMES 15 mg in 3 mL TOPICAL POWDER, FOR SOLUTION [XINGHUI Cell Exosome]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yin Xing Ye + Simvastatin 20 mg (after 7 days of TCM)
Study: 19145455
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol intake (3.3 g/day)
Study: 17925563
Drug: Cisplatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (60 mg/m2) plus gemcitabine (1,000 mg/m2)
Study: 17925563
Drug: Cisplatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (40 mg/m2) plus vinorelbine (25 mg/m2)
Study: 14963675
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg cerivastatin
Study: 11712610
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation combined with soft tissue therapy
Study: 30213365
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg morphine added to PMDI (Group A)
Study: 30213365
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg morphine added to spinal anesthesia (Group B)
Study: 30213365
Drug: No morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: No morphine added (Group C)
Study: 21277694
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to protocol specified radiation therapy guidelines (PP)
Study: 21277694
Drug: Non-adherence to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adherence to protocol specified radiation therapy guidelines (<PP)
Study: 21277694
Drug: Gemcitabine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine treatment with adherence to RT guidelines (PP)
Study: 18307372
Drug: Imipenem administration
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem administration in healthy volunteers
Study: 18307372
Drug: Imipenem administration
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem administration in critical care patients
Study: 16575033
Drug: Remifentanil (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (Group R) - basal infusion of 0.02-0.04 microg x kg(‐1) x min(‐1) with self-administered bolus doses of 0.3 microg x kg(‐1) i.v. every minute as required.
Study: 16575033
Drug: Propofol (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (Group P) - initial plasma target concentration set at 3-4 microg x mL(‐1).
Study: 12679757
Drug: Oral glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glycoprotein IIb/IIIa antagonist orbofiban plus aspirin
Study: 11294060
Drug: Amisulpride (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (300 mg daily)
Study: 11294060
Drug: Amisulpride (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (400 to 800 mg/day, up to 1,200 mg/day)
Study: 2866133
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg at bedtime
Study: 2866133
Drug: famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 20 mg b.i.d.
Study: 2866133
Drug: famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine 40 mg b.i.d.
Study: 25378974
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pravastatin
Study: 22722481
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of tegafur suppositories (group A)
Study: 22722481
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative treatment (group B)
Study: 17590291
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh alone (monotherapy)
Study: 17590291
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh in combination with St. John's wort (combination therapy)
Study: 17590291
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (Black cohosh alone and combination therapy)
Study: 8527271
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg oral ketoprofen
Study: 8527271
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral ketoprofen
Study: 8527271
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg i.v. ketoprofen
Study: 8527271
Drug: R-ketoprofen (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-ketoprofen (oral administration)
Study: 31264282
Drug: Extra-fine particle
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-fine particle hydrofluoroalkane beclomethasone dipropionate (mean dose 355µg) after switching from fine particle ICS (mean dose 710µg)
Study: 27868321
Drug: sacubitril/valsartan 97/103
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 97/103 mg b.i.d.
Study: 27868321
Drug: enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 10 mg b.i.d.
Study: 12764905
Drug: Shengfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengfu Injection (SFI) plus chemotherapy
Study: 11054326
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide sustained drug delivery device
Study: 12206030
Drug: Colgate Optimized
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Optimized Stannous Fluoride (COSF) dentifrice, containing 0.454% stannous fluoride, stannous chloride, polyphosphate, and citrate in a silica base, used twice daily for 6 months.
Study: 31511069
Drug: Atezolizumab (anti-PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (anti-PD-L1 antibody) treatment
Study: 18775942
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) in addition to standard care
Study: 9149190
Drug: Oral preparation
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral preparation (one bottle of magnesium citrate and two 'Dulcolax' tablets)
Study: 9149190
Drug: Enema preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enema preparation (two Fleet's enemas)
Study: 8196323
Drug: gelatin aiconol
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin aiconol in capsules (Group 4, 40 subjects)
Study: 29182212
Drug: Self-etch approach
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-etch approach using a Universal dentine bonding agent (Scotchbond Universal)
Study: 21645332
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg perhexiline maleate
Study: 19546692
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 0.05 mg/kg
Study: 19546692
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 0.2 mg/kg
Study: 19546692
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin 0.4 mg/kg
Study: 16988202
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg administered as a 15-minute 50-mL intravenous infusion
Study: 16988202
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg administered as a 30-second 5-mL infusion
Study: 30121611
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support system plus automated daily supportive/reminder text messages
Study: 30121611
Drug: Automated daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated daily supportive/reminder text messages alone
Study: 30121611
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual follow-up care
Study: 23314695
Drug: IgM-enriched immunoglobulin
Normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgM-enriched immunoglobulin (5 ml/kg via 8 h IV-infusion for three consecutive days)
Study: 23314695
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 ml/kg via 8 h IV-infusion for three consecutive days)
Study: 19082406
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of 0.5% hyperbaric bupivacaine with 2.5 microg of sufentanil and 30 microg of clonidine (CLON/HYPER Group)
Study: 19082406
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of 0.5% isobaric bupivacaine with 2.5 microg of sufentanil and 30 microg of clonidine (CLON/ISO Group)
Study: 16210048
Drug: IVL745 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVL745 (20 mg, twice daily for 7 days)
Study: 2473515
Drug: Colloid cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid cardioplegic solution (35 g dextran 40 added to St Thomas II solution)
Study: 2473515
Drug: Standard crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard crystalloid cardioplegic solution
Study: 30656460
Drug: Prospective ECG-triggered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective ECG-triggered sequential protocol (group 1)
Study: 25008877
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment (200 IU/(kg.d) by intravenous infusion for 7 days)
Study: 21859516
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention consisting of joint meal preparation and activities for children and parents, administered once weekly by a nutrition expert for 6 months.
Study: 15842140
Drug: Shennong No.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shennong No. 33 (SN33) in addition to comprehensive therapy
Study: 15842140
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy without SN33
Study: 12855972
Drug: Treatment Group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Group (prophylactic macular photocoagulation)
Study: 12855972
Drug: No Treatment
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Treatment Group (control)
Study: 10569644
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (LA) 600 mg/d
Study: 10569644
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LA and AT
Study: 7063290
Drug: Flunisolide aerosol
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide aerosol (0.5 mg twice a day)
Study: 29381789
Drug: Automated Self‐Administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated Self‐Administered 24‐h recalls (ASA24s)
Study: 24707021
Drug: Lovaza (3360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza (3360 mg docosahexaenoic acid + eicosapentaenoic acid per day)
Study: 10220696
Drug: Steroid pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid pretreatment (methylprednisolone, 30 mg/kg)
Study: 7880703
Drug: Bupivacaine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 50 mg
Study: 7880703
Drug: Fentanyl in
Normalized name: fentanyl Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl in 0.25% bupivacaine (25 mg)
Study: 7880703
Drug: Fentanyl in
Normalized name: fentanyl Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl in 0.125% bupivacaine (12.5 mg)
Study: 638249
Drug: Low-dose 'concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose 'concentration x time' (C x T) schedule of 1 mg every 12 hr for 3 days
Study: 638249
Drug: Single injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injections of 12 mg/sq m/dose
Study: 22465047
Drug: 0.006 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.006 mg/kg/day of GH subcutaneously (group A, n=60)
Study: 19204509
Drug: HBOC-201 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOC-201 (up to ten 30 g Hb units)
Study: 15059636
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 IU daily for 6 months
Study: 7538815
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin-6 (rhIL-6) maintenance therapy
Study: 2177394
Drug: Carboplatin (CP)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CP) 167‐436 mg/m2 by intravenous infusion, repeated every 4 weeks, 2‐4 cycles
Study: 2177394
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy containing CP (CE: CP + VP ‐ 16)
Study: 2177394
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy containing DDP (PE: DDP + VP ‐ 16)
Study: 2177394
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy containing CP (CAC: CP + adriamycin + cyclophosphamide)
Study: 2177394
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy containing DDP (PAC: DDP + adriamycin + cyclophosphamide)
Study: 7406654
Drug: Methadyl acetate
Normalized name: Methadyl acetate
DrugBank: Methadyl acetate (DB01433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadyl acetate administered on Friday, starting dose identical to previously established methadone dose, flexible thereafter.
Study: 7406654
Drug: Daily methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily methadone comparison group.
Study: 30229398
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) administered to elderly renal transplant recipients
Study: 21070781
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg/day (once daily)
Study: 21070781
Drug: Mesalamine 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 4.5 g/day
Study: 21070781
Drug: Budesonide 3
Normalized name: budesonide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3 mg/day (3 times daily)